Edition:
United States

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

16.55USD
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
$16.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
46,972
52-wk High
$23.36
52-wk Low
$8.00

Chart for

About

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing... (more)

Overall

Beta: --
Market Cap(Mil.): $338.10
Shares Outstanding(Mil.): 20.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 180.40 17.28
EPS (TTM): -- -- --
ROI: -- -0.52 35.61
ROE: -- -3.30 17.17

BRIEF-Protagonist Therapeutics Granted Two New US Patents For Peptide Drug Candidates PTG-100 And PTG-300

* PROTAGONIST THERAPEUTICS GRANTED TWO NEW US PATENTS FOR PEPTIDE DRUG CANDIDATES PTG-100 AND PTG-300 Source text for Eikon: Further company coverage:

Jan 04 2018

BRIEF-Protagonist Therapeutics Appoints Sarah Noonberg To Board

* PROTAGONIST THERAPEUTICS APPOINTS SARAH NOONBERG TO THE BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Dec 14 2017

BRIEF-Protagonist Therapeutics Announces Final Phase 1 Study Results With Novel Hepcidin Mimetic, PTG-300

* PROTAGONIST THERAPEUTICS ANNOUNCES FINAL PHASE 1 STUDY RESULTS WITH NOVEL HEPCIDIN MIMETIC, PTG-300

Dec 14 2017

BRIEF-Protagonist Therapeutics initiates phase 1 trial of oral peptide PTG-200

* Protagonist Therapeutics initiates phase 1 trial of oral peptide IL-23 receptor antagonist, PTG-200

Nov 09 2017

BRIEF-Protagonist Therapeutics Q3 ‍net loss per share $0.29​

* Protagonist Therapeutics reports third quarter 2017 financial results and provides corporate update

Nov 06 2017

BRIEF-Protagonist Therapeutics prices offering of 3.53 mln common shares at $17 per share

* Says public offering of 3.53 million common shares priced at $17.00 per share Source text for Eikon: Further company coverage:

Oct 11 2017

BRIEF-Protagonist Therapeutics announces proposed public offering of common stock

* Protagonist Therapeutics announces proposed public offering of common stock

Oct 11 2017

BRIEF-Protagonist Therapeutics Inc files for mixed shelf of up to $200 million - SEC filing ‍​

* Protagonist Therapeutics Inc files for mixed shelf of up to $200 million - SEC filing ‍​ Source text: (http://bit.ly/2xDBQBh) Further company coverage:

Sep 01 2017

BRIEF-Protagonist Therapeutics announces closing of Janssen license

* Protagonist Therapeutics announces closing of Janssen license and collaboration agreement for PTG-200 and receipt of $50 million payment

Aug 24 2017

Earnings vs. Estimates